Open AccessCarbamazepine-associated drug reaction with eosinophilia and systemic symptoms syndrome
Author(s) -
Ankush Sharma,
Ekta Joshi,
Nitin Gupta,
Monika Joshi
Publication year - 2021
Publication title -
journal of pediatric neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
eISSN - 1998-3948
pISSN - 1817-1745
DOI - 10.4103/jpn.jpn_126_15
Subject(s) - medicine , carbamazepine , sulfasalazine , eosinophilia , hypersensitivity reaction , dapsone , mucocutaneous zone , methylprednisolone , phenytoin , drug , adverse drug reaction , dermatology , pharmacology , anesthesia , immunology , epilepsy , disease , psychiatry , ulcerative colitis
Drug reaction with eosinophilia and systemic symptoms syndrome is a severe type IV (delayed T-cell-dependent reaction) hypersensitivity reaction, characterized by fever, mucocutaneous eruptions, eosinophilia, and systemic inflammatory involvement. It usually begins a few weeks after the exposure to offending drug. Commonly implicated drugs are aromatic anticonvulsants (phenytoin, phenobarbitone, and carbamazepine) and sulfa drugs (sulfonamides, sulfasalazine, and dapsone). It is a potentially life-threatening hypersensitivity reaction. Here we report a case of drug reaction with eosinophilia and systemic symptoms syndrome associated with carbamazepine, which was successfully treated with intravenous methylprednisolone.